No Data
Noil Immune --- For the fiscal year ending December 2024, the in-house drug development business and the joint pipeline will continue to be promoted.
Noil Immune Biotech <4893> announced its financial results for the fiscal year ending December 2024 on the 14th. Business revenue was 0.007 billion yen (compared to 0.316 billion yen in the previous term), operating loss was 1.069 billion yen (compared to a loss of 0.775 billion yen in the previous term), recurring loss was 0.962 billion yen (compared to a loss of 1.127 billion yen in the previous term), and net loss for the year was 0.964 billion yen (compared to a loss of 1.13 billion yen in the previous term). As for the company's business status for the fiscal year, the self-developed drug discovery business based on PRIME technology and the joint pipeline will continue.
The Nikkei average rose by 24 yen and slightly rebounded, while many stocks on the Main Board fell amid a wait-and-see attitude = afternoon session on the 17th.
On the 17th, the Nikkei average stock price in the afternoon session rose slightly by 24.82 yen to reach 39,174.25 yen, showing a minor rebound. The TOPIX (Tokyo Stock Price Index) increased by 7.69 points to 2,766.90 points. The morning started with a dominant Sell, but transitioned to an upward trend. At 9:17 AM, the Nikkei average hit 39,238.75 yen, up 89.32 yen. Meanwhile, President Trump is considering imposing tariffs on imported Autos around April 2, which is a burden on related stocks.
Today's flows: 02/17 Sony Group saw an inflow of JPY¥ 9.88 billion, Lasertec saw an outflow of JPY¥ 6.72 billion
On February 17th, the TSE Main Market saw an inflow of JPY¥ 794.4 billion and an outflow of JPY¥ 840.75 billion.$Sony Group(6758.JP)$, $Mitsubishi UFJ Financial Group(8306.JP)$ and $SoftBank Group(998
List of cloud break stocks (Part 2) [Ichimoku Kinko Hyo - List of cloud break stocks]
○ List of stocks that broke through the clouds Market Code Stock Name Closing Price Leading Span A Leading Span B Main Board <1860> Toda Corporation 951 953 958 <1888> Wakachiku Construction 3685 3720 <1968> Taihei Electric 4980 5075 5085 <1969> Takasago Thermal 5406 6254.25 5572.5 <2108> Sugar Beet 2391 2398.5 2445 <2335> Ki
In the fiscal year ending December 2024, VIS will promote mRNA-targeted small molecule drug discovery business and the creation of its own pipeline.
Veritas In Silico <130A> announced its fiscal results for the year ending December 2024 on the 13th. Business revenue decreased by 46.0% compared to the previous year to 0.194 billion yen, with an operating loss of 0.212 billion yen (compared to a profit of 0.037 billion yen in the previous term), an ordinary loss of 0.233 billion yen (compared to a profit of 0.035 billion yen in the previous term), and a net loss of 0.236 billion yen (compared to a profit of 0.033 billion yen in the previous term). In the company's mRNA-targeted small molecule drug discovery business, the drug discovery platform ibVIS(R) is being utilized, and TORAY INDS INC <3402>.
Rating Information (Target Price Change - Part 2) = Nissui, F&LC, ETC.
◎ Mizuho Securities (three-tier: Buy > Hold > underperform) Nissui <1332.T> -- "Buy" → "Buy", 1270 yen → 1300 yen Ariake <2815.T> -- "Buy" → "Buy", 7500 yen → 7700 yen F&LC <3563.T> -- "Buy" → "Buy", 4000 yen → 4800 yen Goldwin <8111.T> -- "Buy" → "Buy", 15000 yen → 13000 yen Sumitomo Warehouse <9303.T> -- "Hold" → "Hold", 2600 yen →
